financetom
MMLP
financetom
/
Energy
/
MMLP
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
Martin Midstream Partners L.P.MMLP
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
Market Cap
108.66M
Revenue (ttm)
707.62M
Net Income (ttm)
-5.08M
Shares Out
39.80M
EPS (ttm)
-0.13
PE Ratio
n/a
Forward PE
n/a
Dividend
$0.02 (0.73%)
Ex-Dividend Date
Feb 7, 2025
Volume
23,566
Open
2.780
Previous Close
2.780
Day's Range
2.670 - 2.870
52-Week Range
2.360 - 4.130
Beta
1.75
Analysts
n/a
Price Target
n/a
Earnings Date
Apr 16, 2025
Description >

Martin Midstream Partners L.P., together with its subsidiaries, provides terminalling, processing, storage, and packaging services for petroleum products and by-products primarily in the United States.

The company operates in four segments: Terminalling and Storage, Transportation, Sulfur Services, and Natural Gas Liquids.

The company's Terminalling and Storage segment owns or operates 14 marine shore-based terminal facilities and 13 specialty terminal facilities that provide storage, refining, blending, packaging, and handling services for producers and suppliers of petroleum products and by-products.

This segment also offers land rental services to oil and gas companies, as well as storage and handling services for lubricants and fuels.

Its Transportation segment operates a fleet of 700 trucks and 1,200 tank trailers; and 27 inland marine tank barges, 15 inland push boats, and 1 articulated offshore tug and barge unit to transport petroleum products and by-products, petrochemicals, and chemicals.

The company's Sulfur Services segment processes molten sulfur into prilled or pelletized sulfur, which is used in the production of fertilizers and industrial chemicals.

Its Natural Gas Liquids segment stores, distributes, and transports natural gas liquids for wholesale deliveries to refineries, industrial natural gas liquid users, and propane retailers.

Martin Midstream GP LLC serves as a general partner of the company. Martin Midstream Partners L.P. was incorporated in 2002 and is based in Kilgore, Texas.

Latest News >
Cencora Files Mixed Shelf Registration
Cencora Files Mixed Shelf Registration
Nov 26, 2024
05:23 PM EST, 11/26/2024 (MT Newswires) -- Cencora ( COR ) filed a registration statement with the US Securities and Exchange Commission covering the potential sale of securities from time to time. The prospectus covers common stock, preferred stock, debt securities, depositary shares, warrants, purchase contracts and units, the company said Tuesday in the filing. Net proceeds will be for...
Microchip Technology Insider Sold Shares Worth $317,612, According to a Recent SEC Filing
Microchip Technology Insider Sold Shares Worth $317,612, According to a Recent SEC Filing
Nov 26, 2024
05:22 PM EST, 11/26/2024 (MT Newswires) -- James Eric Bjornholt, Senior Vice President and CFO, on November 25, 2024, sold 4,688 shares in Microchip Technology ( MCHP ) for $317,612. Following the Form 4 filing with the SEC, Bjornholt has control over a total of 33,272 shares of the company, with 33,272 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/827054/000082705424000223/xslF345X05/wk-form4_1732659500.xml ...
Home Bancshares Insider Sold Shares Worth $1,801,250, According to a Recent SEC Filing
Home Bancshares Insider Sold Shares Worth $1,801,250, According to a Recent SEC Filing
Nov 26, 2024
05:22 PM EST, 11/26/2024 (MT Newswires) -- Alex R Lieblong, Director, on November 25, 2024, sold 55,000 shares in Home Bancshares ( HOMB ) for $1,801,250. Following the Form 4 filing with the SEC, Lieblong has control over a total of 571,553 shares of the company, with 571,553 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1331520/000133152024000188/xslF345X05/wk-form4_1732659516.xml ...
PTC Therapeutics' Amyotrophic Lateral Sclerosis Trial Fails to Meet Endpoints; Shares Fall After Hours
PTC Therapeutics' Amyotrophic Lateral Sclerosis Trial Fails to Meet Endpoints; Shares Fall After Hours
Nov 26, 2024
05:23 PM EST, 11/26/2024 (MT Newswires) -- PTC Therapeutics ( PTCT ) said late Tuesday that a global phase 2 trial of Utreloxastat in patients with amyotrophic lateral sclerosis failed to meet its primary and secondary efficacy endpoints. The study didn't meet its primary endpoint of slowing disease progression on the composite ALSFRS-R and mortality analysis, while significance wasn't achieved...
Copyright 2023-2025 - www.financetom.com All Rights Reserved